Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of the long-acting octreotide formulation (Octreotide-Lar) in patients with thyrotropin-secreting pituitary adenomas
Autore:
Caron, P; Arlot, S; Bauters, C; Chanson, P; Kuhn, JM; Pugeat, M; Marechaud, R; Teutsch, C; Vidal, E; Sassano, P;
Indirizzi:
Univ Hosp Rangueil, Dept Endocrinol, Serv Endocrinol & Malad Metab, F-31403 Toulouse, France Univ Hosp Rangueil Toulouse France F-31403 tab, F-31403 Toulouse, France Univ Hosp, Dept Endocrinol, F-80054 Amiens, France Univ Hosp Amiens France F-80054 Dept Endocrinol, F-80054 Amiens, France Univ Hosp, Dept Endocrinol, F-59037 Lille, France Univ Hosp Lille FranceF-59037 p, Dept Endocrinol, F-59037 Lille, France Univ Hosp, Dept Endocrinol, F-94276 Paris, France Univ Hosp Paris FranceF-94276 p, Dept Endocrinol, F-94276 Paris, France Univ Hosp, Dept Endocrinol, F-76233 Rouen, France Univ Hosp Rouen FranceF-76233 p, Dept Endocrinol, F-76233 Rouen, France Univ Hosp, Dept Endocrinol, F-69321 Lyon, France Univ Hosp Lyon France F-69321 osp, Dept Endocrinol, F-69321 Lyon, France Univ Hosp, Dept Endocrinol, F-86021 Poitiers, France Univ Hosp Poitiers France F-86021 t Endocrinol, F-86021 Poitiers, France Univ Hosp, Dept Endocrinol, F-63003 Clermont Ferrand, France Univ Hosp Clermont Ferrand France F-63003 63003 Clermont Ferrand, France Univ Hosp, Dept Endocrinol, F-87042 Limoges, France Univ Hosp Limoges France F-87042 ept Endocrinol, F-87042 Limoges, France Novartis Pharma SA, F-92506 Rueil Malmaison, France Novartis Pharma SA Rueil Malmaison France F-92506 ueil Malmaison, France
Titolo Testata:
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
fascicolo: 6, volume: 86, anno: 2001,
pagine: 2849 - 2853
SICI:
0021-972X(200106)86:6<2849:EOTLOF>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOMATOSTATIN ANALOG LANREOTIDE; SLOW-RELEASE FORMULATION; TSH; SMS-201-995; TUMORS; INHIBITION; RECEPTORS; INVITRO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Caron, P Univ Hosp Rangueil, Dept Endocrinol, Serv Endocrinol & Malad Metab, 1 Ave J Poulhes, F-31403 Toulouse, France Univ Hosp Rangueil 1 Ave J Poulhes Toulouse France F-31403 rance
Citazione:
P. Caron et al., "Efficacy of the long-acting octreotide formulation (Octreotide-Lar) in patients with thyrotropin-secreting pituitary adenomas", J CLIN END, 86(6), 2001, pp. 2849-2853

Abstract

The presence of somatostatin receptors on TSH-secreting pituitary adenomasallows treatment of central hyperthyroidism with somatostatin analogs. Sixwomen and 5 men (mean +/- SEM age, 43 +/- 3 yr) presented TSH-secreting pituitary adenomas (micro, n = 2; macro, n = 9). Seven patients had previously been treated with partial surgical removal (n = 6) and/or external radiation (n = 4) of their adenoma at least 1 yr before the study, whereas 4 patients had not been treated before somatostatin analog therapy. TSH, free T-4, and free T-3 levels were in the normal range during treatment with sc injections (n = 9) or continuous infusion (n = 2) of octreotide (280 +/- 25 mug/day). Mean thyroid hormone levels increased (P < 0.01) after the washout period (34 +/- 6 days). The patients received monthly im injections of 20 mg Octreotide-LAR. In patients with an elevated free T-4 level after 3 months (n = 1) the Octreotide-LAR dose was increased to 30 mg. After 3 months ofOctreotide-LAR treatment, TSH, free T-4/T-3, and <alpha>-subunit levels decreased, and 10 patients were euthyroid with normal free T-4 levels. These results remained at the same level over the next 3 months. There were no statistically significant differences in the TSH and free T-4 responses to scoctreotide or im Octreotide-LAR between previously untreated patients and patients who had undergone surgical resection and/or pituitary radiation before somatostatin analog treatment. During Octreotide-LAR treatment, minor digestive problems or moderate discomfort at the injection site, lasting less than 48 h, were reported in 6 and 5 patients, respectively. Gallbladder echographies did not reveal new gallstones during Octreotide-LAR treatment. In conclusion, this study shows that monthly im Octreotide-LAR is as effective as daily sc octreotide in controlling hyperthyroidism in patients withTSH-secreting pituitary adenomas, in both previously untreated patients and patients treated with surgery and/or pituitary radiotherapy. Octreotide-LAR is well tolerated, except for minor digestive problems or mild pain at the injection site. Therefore, Octreotide-LAR appears to be a useful therapeutic tool to facilitate medical treatment of TSH-secreting pituitary adenomas in patients who need long-term somatostatin analog therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 15:38:26